Efficacy Of Intrapleural Streptokinase Therapy In Tubercular Pleural Effusions - A Randomised Controlled Trial

Gaude, Gajanan S; Sandeep, H

doi:10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a4912

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 Similar excellent results have been reported. [15][16][17][18][19][20][21][22][23][24][25] Intrapleural streptokinase was found to be extremely safe in our study with no major adverse effects. Although major bleeding, anaphylaxis, respiratory failure, fever, arthralgia, pleuritic chest pain, nausea and headache have been reported, 26,27 we believe that a short duration of ICDT clamping of two hours and the use of purified form of streptokinase, 28 will practically eliminate these complications if there is rigorous case selection, and early initiation of treatment.…”

Section: Discussionmentioning

confidence: 86%

Efficacy and safety of intrapleural streptokinase in tubercular empyema thoracis – old wine in new wineskin

et al. 2021

View full text Add to dashboard Cite

Tubercular empyema thoracis continues to be one of the leading causes of morbidity in low-income countries. Despite antitubercular therapy (ATT) and thoracostomy, empyema drainage is hampered by multiple septations, loculations, debris, and blood clots leading to complications. In a comparative experimental study to estimate the efficacy and safety of intrapleural streptokinase (IPSTK) in tubercular empyema, 30 cases of chronic multiloculated tubercular empyema were compared by radiological improvement by chest radiography, duration and volume of fluid drained, and degree of dyspnoea according to the modified Borg scale, depending on whether streptokinase was used or not. The former scored on all counts; we therefore conclude that intrapleural streptokinase is a safe, efficacious intervention in tubercular empyema. It decreases morbidity and reduces the need for surgery.

show abstract